Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Geron Corp (GB:0IV3)
LSE:0IV3
Geron (0IV3) Share Price & Analysis
0 Followers
0IV3 Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$1.73 - $4.01
Previous Close$3.67
Volume4.15K
Average Volume (3M)23.83K
Market Cap
$2.17B
Enterprise Value$1.91B
Total Cash (Recent Filing)$313.53M
Total Debt (Recent Filing)$56.02M
Price to Earnings (P/E)-11.3
Beta0.64
Next Earnings
May 06, 2024EPS Estimate
-$0.1Last Dividend Ex-Date
Jul 22, 2014Dividend YieldN/A
Share Statistics
EPS (TTM)-0.32
Shares Outstanding546,059,309
10 Day Avg. Volume2,494
30 Day Avg. Volume23,832
Standard Deviation0.32
R-Squared0.00
Alpha0.04
Financial Highlights & Ratios
Price to Book (P/B)8.13
Price to Sales (P/S)10058.13
Price to Cash Flow (P/CF)-12.30
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue6.03K
Enterprise Value/Gross Profit3.21K
Enterprise Value/Ebitda-10.91
Forecast
1Y Price Target
$5.08Price Target Upside38.34% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering6
Geron News
Bulls Say, Bears Say
Bulls Say
Clinical Data And Healthcare Professional SupportStrong support from physicians and compelling clinical data underline the high probability of imetelstat's approval, with significant benefits highlighted in patient quality of life.
Company Leadership And Market EngagementGeron's leadership, including CEO John Scarlett, demonstrates proactive engagement with the investment community through active participation in key healthcare conferences.
Drug Approval And Commercial PotentialImetelstat has received a favorable vote from the FDA Advisory Committee, bolstering analyst expectations for its potential approval and robust commercial prospects.
Bears Say
Financial PressureThe company's cash runway guidance has been shortened, indicating potential financial pressure.
Regulatory ChallengesFDA reviewers maintained a fairly strongly negative tone throughout the discussion.
Safety ConcernsSafety issues were highlighted by the FDA, questioning the risks associated with cytopenias and their clinical sequelae.
---
Options Prices
Currently, No data available
---
Ownership Overview
1.70% Insiders
8.61% Mutual Funds
14.77% Other Institutional Investors
74.93% Public Companies and
Individual Investors
0IV3 FAQ
What was Geron Corp’s price range in the past 12 months?
Geron Corp lowest share price was $1.73 and its highest was $4.00 in the past 12 months.
What is Geron Corp’s market cap?
Currently, no data Available
When is Geron Corp’s upcoming earnings report date?
Geron Corp’s upcoming earnings report date is May 06, 2024 which is in 12 days.
How were Geron Corp’s earnings last quarter?
Geron Corp released its earnings results on Feb 28, 2024. The company reported -$0.09 earnings per share for the quarter, beating the consensus estimate of -$0.105 by $0.015.
Is Geron Corp overvalued?
According to Wall Street analysts Geron Corp’s price is currently Undervalued.
Does Geron Corp pay dividends?
Geron Corp pays a Notavailable dividend of $0.15 which represents an annual dividend yield of N/A. See more information on Geron Corp dividends here
What is Geron Corp’s EPS estimate?
Geron Corp’s EPS estimate is -$0.1.
How many shares outstanding does Geron Corp have?
Geron Corp has 588,059,300 shares outstanding.
What happened to Geron Corp’s price movement after its last earnings report?
Geron Corp reported an EPS of -$0.09 in its last earnings report, beating expectations of -$0.105. Following the earnings report the stock price went down -3.445%.
Which hedge fund is a major shareholder of Geron Corp?
Among the largest hedge funds holding Geron Corp’s share is RA Capital Management. It holds Geron Corp’s shares valued at 97M.
---
Geron Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$5.08 (38.34% Upside)
$5.08 (38.34% Upside)
Blogger Sentiment
Bullish
GB:0IV3 Sentiment 100%
Sector Average 70%
Sector Average 70%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
48.19%
12-Months-Change
Fundamentals
Return on Equity
-112.29%
Trailing 12-Months
Asset Growth
106.78%
Trailing 12-Months
Company Description
Geron Corp
Geron Corp. operates as a biotechnology company. It develops a telomerase inhibitor, imetelstat, in hematologic myeloid malignancies. The company was founded by Michael D. West on November 28, 1990 and is headquartered in Menlo Park, CA.
---
0IV3 Company Deck
---
0IV3 Earnings Call
Q4 2024
0:00 / 0:00
---
0IV3 Stock 12 Months Forecast
Average Price Target
$5.08
▲(38.34% Upside)
Technical Analysis
Geron
―
ACADIA Pharmaceuticals
―
Kala Pharmaceuticals
―
MacroGenics
―
Protagonist Therapeutics
―
Best Analysts Covering 0IV3
1 Year
1 Year Success Rate
11/12 ratings generated profit
1 Year Average Return
+59.38%
reiterated a buy rating last month
Copying Joel Beatty's trades and holding each position for 1 Year would result in 91.67% of your transactions generating a profit, with an average return of +59.38% per trade.
---